Thor Medical completes AlphaOne facility construction

Thor Medical, a member of Oslo Cancer Cluster, has announced it has finished building its AlphaOne production facility at Herøya Industrial Park, reaching what is known as “mechanical completion.” This means all major construction and installation work is done.

“This is a major achievement for Thor Medical and a testament to the strong execution capabilities of our team and partners,” said Jasper Kurth, Chief Executive Officer of Thor Medical ASA.

Isotopes against cancer

The AlphaOne facility will produce alpha-emitting radioisotopes, which are used in some types of targeted cancer treatments. Demand for these materials is growing as more radiopharmaceutical therapies are developed.

“Reaching Mechanical Completion, alongside the successful start of commissioning, keeps us firmly on track toward commencing production in the third quarter and delivering on our strategy to become a leading supplier of alpha-emitting radioisotopes for cancer treatment,” Kurth added.

A global supplier

When it becomes operational, the plant is expected to add to the global supply of these specialised cancer treatment components.

The facility has now moved into the commissioning phase. In this stage, systems and equipment are tested and checked to make sure they are ready for operation. Commissioning started partly in March and will continue as the company prepares to begin production in the third quarter of this year.

• Read more at Thor Medical’s website